Head-To-Head Review: Oncocyte (NASDAQ:IMDX) vs. Sera Prognostics (NASDAQ:SERA)

Sera Prognostics (NASDAQ:SERA) and Oncocyte (NASDAQ:IMDX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Sera Prognostics and Oncocyte”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80,000.00	1,050.36	-$31.93 million	($0.67)	-3.18
Oncocyte	$4.05 million	33.45	-$50.22 million	($1.49)	-2.78

Sera Prognostics has higher earnings, but lower revenue than Oncocyte. Sera Prognostics is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Sera Prognostics and Oncocyte, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1	0	1	1	2.67
Oncocyte	1	0	2	0	2.33

Sera Prognostics presently has a consensus target price of $5.50, suggesting a potential upside of 158.22%. Oncocyte has a consensus target price of $10.50, suggesting a potential upside of 153.62%. Given Sera Prognostics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Sera Prognostics is more favorable than Oncocyte.

Volatility and Risk

Sera Prognostics has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Oncocyte has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.

Insider & Institutional Ownership

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 55.3% of Oncocyte shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by insiders. Comparatively, 2.2% of Oncocyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Sera Prognostics and Oncocyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Oncocyte	-2,955.63%	N/A	-107.52%

Summary

Sera Prognostics beats Oncocyte on 8 of the 15 factors compared between the two stocks.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

About Oncocyte

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.